Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Exclusion Criteria

• •Prior vaccination with EV71 vaccine;
• •History of hand，foot and mouth disease;
• •Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
• •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
• •Autoimmune diseases or immunodeficiency/immunosuppression;
• •Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
• •History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy;
• •Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
• •Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months;
• •Receipt of any of the following products:
• •1. Blood product within 3 months prior to study entry;
• •2. Any live attenuated vaccine within 14 days prior to study entry;
• •3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
• •4. Any other study drugs within 30 days prior to study entry;
• •Acute disease or acute stage of chronic disease within 7 days prior to study entry;
• •Axillary temperature \> 37.0℃;
• •Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.